Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
Launched by UNIVERSITY OF PENNSYLVANIA · Nov 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The LiverWatch clinical trial is exploring a new way to help people with advanced liver disease, specifically cirrhosis. This study aims to improve health outcomes by using a home-based program that includes personalized nutrition advice, physical activity encouragement, and regular check-ins about symptoms. Participants will be randomly assigned to either receive standard care or take part in the LiverWatch program, where they will get a fitness tracker to monitor their steps and be rewarded for increasing their physical activity.
To join the trial, individuals must be at least 18 years old, speak English, and live at home with a diagnosis of cirrhosis. Participants should be willing to use a smartphone to receive updates and engage with the study staff. They will be asked to wear fitness trackers and monitor their health while receiving support and education about managing their condition. This trial is currently recruiting participants and aims to provide valuable insights into how remote monitoring can enhance care for those living with cirrhosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English speaking
- • Aged 18 years or older
- • Home-dwelling
- • Diagnosis of cirrhosis- Child Turcotte-Pugh (CTP) B or C or a complication in the past 6 months (CTP B or higher, hepatic encephalopathy, variceal bleeding, fluid overload, liver-related hospitalization, or requiring symptom management with diuretics, non-absorbable disaccharides, rifaximin, nonselective beta blockers)
- • Patient and/or caregiver is able and willing to receive SMS text messages
- • Willing and able to wear personal fitness trackers and engage with study staff
- Exclusion Criteria:
- • No access to a smartphone
- • Non-home dwelling
- • On hospice care
- • Model for end stage liver disease (MELD) score ≥30
- • Advanced hepatocellular carcinoma, BCLC C or higher
- • Hospitalization within the last 30 days
- • Deemed not appropriate by treating physician for medical reasons
- • Enrolled in other dietary or physical activity interventions
- • Receiving physical therapy as standard of care
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Philadelphia, Pennsylvania, United States
Ann Arbor, Michigan, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported